Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment.

Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive up to $405 million in

Read the full 398 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE